The stock rose 9.1% following earnings, reflecting investor approval of the significant regulatory milestone moving medical cannabis to Schedule III and solid progress in leasing activity, which eased concerns about portfolio stability and growth prospects.

• Total revenues reached $69 million with AFFO of $53.4 million, or $1.88 per share, stable quarter-over-quarter.
• Completed leases across 5 properties totaling 389,000 square feet year-to-date, including full leasing of all former Gold Flora assets (330,000 sq. ft.).
• Raised $128 million in gross capital year-to-date, with additional financing underway to address bond maturities and support growth.
• The DOJ’s rescheduling of FDA-approved medical cannabis to Schedule III is expected to improve operator economics, reduce tax burdens, and enhance access to capital.
• Active resolution of prior lease defaults, including PharmaCann litigation, supports portfolio stabilization and retenanting efforts.